Vortex Keratopathy in a Patient Receiving Vandetanib for Non-Small Cell Lung Cancer
Korean Journal of Ophthalmology
; : 355-357, 2011.
Article
in En
| WPRIM
| ID: wpr-15768
Responsible library:
WPRO
ABSTRACT
We report a case of vortex keratopathy in a patient treated with vandetanib for non-small cell lung cancer (NSCLC). A 44-year-old female who underwent two cycles of chemotherapy for NSCLC complained of visual blurring in both eyes after the initiation of vandetanib, an anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor receptor 2 protein tyrosine kinase inhibitor. On ophthalmic examination, visual acuities were 20 / 20 OU and, with the exception of diffuse vortex keratopathy in both eyes, other findings were unremarkable. Vandetanib is believed to have caused vortex keratopathy in this patient. Anti-EGFR properties affecting normal corneal epithelial cell migration and wound healing or drug associated metabolite deposition, which is the case in numerous drug-associated vortex keratopathies, may be possible underlying mechanisms in the formation of this corneal complication.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Piperidines
/
Quinazolines
/
Visual Acuity
/
Follow-Up Studies
/
Carcinoma, Non-Small-Cell Lung
/
Cornea
/
Corneal Diseases
/
Microscopy, Acoustic
/
Diagnosis, Differential
/
Dose-Response Relationship, Drug
Type of study:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
Limits:
Adult
/
Female
/
Humans
Language:
En
Journal:
Korean Journal of Ophthalmology
Year:
2011
Type:
Article